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Abstract
Introduction: Despite the availability of preventive strategies (screening tests and vaccines), cervical cancer continues to
impose a significant health burden in low- and medium-resourced countries. HIV-infected women are at increased risk for
infection with human papillomavirus (HPV) and thus development of cervical squamous intraepithelial neoplasia (CIN).
Methods: Study participants included HIV-infected women enrolling the prospective open cohort of Evandro Chagas
Clinical Research Institute, Oswaldo Cruz Foundation (IPEC/FIOCRUZ). At cohort entry, women were subjected to
conventional Papanicolaou test, HPV-DNA test and colposcopy; lesions suspicious for CIN were biopsied. Histopathology
report was based on directed biopsy or on specimens obtained by excision of the transformation zone or cervical
conization. Poisson regression modeling was used to assess factors associated with CIN2+ diagnosis.
Results: The median age of the 366 HIV-infected women included in the study was 34 years (interquartile range: 28–41
years). The prevalence of CIN1, CIN2 and CIN3 were 20.0%, 3.5%, and 2.2%, respectively. One woman was found to have
cervical cancer. The prevalence of CIN2+ was 6.0%. Factors associated with CIN2+ diagnosis in the multivariate model were
age, years compared to$35 years (aPR = 3.22 95%CI 1.23–8.39), current tobacco use (aPR = 3.69 95%CI 1.54–8.78), nadir
CD4 T-cell count ,350 cells/mm3 when compared to $ 350 cells/mm3 (aPR = 6.03 95%CI 1.50–24.3) and concomitant
diagnosis of vulvar and/or vaginal intraepithelial lesion (aPR = 2.68 95%CI 0.99–7.24).
Discussion: Increased survival through wide-spread use of highly active antiretroviral therapy might allow for the
development of cervical cancer. In Brazil, limited cytology screening and gynecological care adds further complexity to the
HIV-HPV co-infection problem. Integrated HIV care and cervical cancer prevention programs are needed for the prevention
of cervical cancer mortality in this group of women.
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Introduction
The HIV/AIDS pandemic continues to spread in many parts of
the world. In Latin American countries, as a result of increased
heterosexual transmission, there is now a growing number of HIV
infected women [1]. Indeed, the impact of HIV/AIDS pandemic
is most pronounced among the poorest and the youngest, with
women being overrepresented in these groups [1]. Several studies
have consistently identified that HIV-infected women, especially
those with low CD4 T-cell counts, are at increased risk for
infection with human papillomavirus (HPV) [2,3,4], the etiologic
agent of cervical cancer and its precursor lesions. HIV-infected
women also have higher rates of infection with high-risk HPV
types, are frequently infected with multiple HPV types, and have a
higher chance of presenting with a persistent infection [2,3,4].
Furthermore, HIV infection has been shown to increase a
woman’s risk of developing cervical squamous intraepithelial
neoplasia (CIN) and invasive cervical cancer [5,6].
Cervical cancer continues to impose a significant health burden
in low- and medium-resourced countries of sub-Saharan Africa,
South and South East Asia and Latin America [7,8,9], despite its
high preventability by screening and human papillomavirus (HPV)
vaccination. In Brazil, cervical cancer is the second most common
form of cancer among women and the fourth cause of death by
cancer [10]. In contrast to high-resource countries, middle- and
low-resource countries provide little or no access to cervical cancer
screening for women, regardless of HIV status [6]. Although the
increased antiretroviral therapy delivery in middle- and low-
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resource countries has greatly decreased the burden of several
opportunistic infections, the impact of the partial immune
restoration induced by antiretroviral therapy on the natural
history of HPV infection seems modest, at best [11]. In fact, HIV-
infected women remain at a continued substantial risk for cervical
neoplasia, even if they receive antiretroviral therapy [3,6].
Studies that use cervical cytology for the diagnosis of CIN rather
than histopathology are perceived as less reliable. In addition to
the possibility of missing true disease (that is, of a false negative
report), there is also the possibility of disease misclassification or of
false positive reports when using cytology. In the ASCUS/LSIL
Triage Study for Cervical Cancer (ALTS), 40% of cases classified
as high-grade intraepithelial lesions with cytology that were
followed with histopathology were less severe than CIN2+ during
follow-up [12].
The purpose of this study was to assess the prevalence and
factors associated with colposcopy-histopathology confirmed CIN
in the baseline assessment of the cohort of HIV-infected women of
the Evandro Chagas Clinical Research Institute, Oswaldo Cruz
Foundation, located in Rio de Janeiro, Brazil.
Methods
Ethics Statement: Written informed consent was obtained for all
women. The study protocol was approved by the ethics committee
of Evandro Chagas Clinical Research Institute, Oswaldo Cruz
Foundation.
To study the natural history of HIV infection in women, a
prospective open cohort was established at the Evandro Chagas
Clinical Research Institute (IPEC), Oswaldo Cruz Foundation
(FIOCRUZ), Rio de Janeiro, Brazil. Eligibility criteria include
documented HIV-status and written informed consent that
inquires on the willingness to participate and attend all medical
appointments. Participants are included in the cohort regardless of
their CD4+ cell counts or current antiretroviral status. Study visits
occur at 6-months intervals when a structured questionnaire is
administered inquiring on socio-demographic information, sexual
and reproductive history, as well as medical history relevant to
HIV/AIDS and cervical cancer (including previous sexually
transmitted infections). Clinical and laboratory assessment in-
cludes a pelvic examination with specimen collection. Women
with evidence of sexually transmitted infections are managed
according to the Brazilian guidelines [13].
At cohort entry, women were subjected to conventional
Papanicolaou (Pap) test, HPV-DNA test and colposcopy. Pap test
was performed with an Ayre’s wooden spatula and an endocervical
brush and classified according to the Bethesda 2001 classification
system. The Hybrid Capture 2 assay (HC2, Qiagen, Gaithers-
burg/MD/USA) with probes for high- and low-risk types was the
HPV-DNA test used. Specimens were obtained with a cervical
brush and stored in frozen conservative media until processing.
The HC2 assay used in this study categorized HPVs into two
groups: low risk (which includes HPV 6, 11, 42, 43 and 44), and
high risk (which includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68).
All women were referred to colposcopy irrespective of the Pap
test results. A standardized full colposcopic evaluation including
the vulvar, vaginal, and perianal regions was performed by trained
gynecologists. Colposcopic results were classified according to the
International Cervical Pathology and Colposcopy Federation 2002
[14].
Histopathology result was given based on directed biopsy or on
specimens obtained by excision of the transformation zone or
conization. These procedures were performed following the
Brazilian guidelines [15] and may be summarized as follows:
Large Loop Excision of the transformation zone (LLETZ) [16]
was performed when directed biopsy showed CIN2+ or when the
Pap test showed high-grade intraepithelial neoplasia and colpos-
copy was satisfactory showing major changes (in a See & Treat
approach). Conization was performed when directed biopsy
showed CIN2+ in women with unsatisfactory colposcopy or with
a transformation zone extending beyond the first centimeter of the
endocervix, or when the Pap test showed high-grade intraepithelial
neoplasia and colposcopy showed major changes but was
unsatisfactory. Directed biopsies were performed when minor
colposcopic changes were observed but it was not possible to
exclude CIN2+ and the Pap test showed LSIL, ASC or was
normal. Histopathology samples from these procedures were
analyzed by non-blinded pathologists from the Cervical Pathology
Referral Center, located in Fernandes Figueira Institute/FIO-
CRUZ, who reported diagnosis by consensus. Histopathology
results were classified into five categories of increasing disease
severity: normal/no neoplastic abnormalities, CIN1, CIN2, CIN3,
and ICC [17]. Vulvar and vaginal biopsies were classified as
normal or vulvar or vaginal intraepithelial neoplasia, respectively.
The final diagnosis was based on histopathology for those who
underwent invasive procedures and on colposcopy in women who
had no clinical indication for undergoing invasive procedures or
for whom histopathology was inconclusive. All CIN 2+/ICC
diagnosis were histopathologically reported.
CD4+ T-cell counts (Becton Dickinson FACScan) were
obtained from the participant’s medical record. The nadir
CD4+ T-cell count was defined as the lowest level of immuno-
suppression since HIV diagnosis up until cohort entry. The
baseline CD4+ T-cell count was defined as the measured level of
immunosuppression observed within 90 days of cohort entry.
Women were considered to be under highly-active antiretroviral
treatment (HAART) if they were under HAART for at least two
months before cohort enrollment.
For the statistical analyses, the five diagnostic categories were
collapsed into a binary outcome variable: negative or CIN1 (Neg/
CIN1) and CIN2+. A Poisson regression analysis was used to
estimate the degree of association of factors with CIN2+, using
women with a Neg/CIN1 diagnosis as the reference category. For
the correct estimation of the parameters, the quasi-Poisson model
was used because the data showed over-dispersion when the
Poisson model was applied [18,19,20]. A bivariate analysis was
first conducted to determine which factors would enter the initial
multivariate model. Factors associated with a CIN2+ diagnosis
assuming a significance threshold of 20% were included in the
initial multivariate model. The final model was reached by
removing variables with less than 5% significance. Variables with
borderline significance, but for which biological plausibility is
suspected, were kept in the final model. In addition, a stratified
analysis was conducted within the sub-group of women who were
infected with high-risk HPV. Following the above mentioned
procedures, we also estimated the factors associated with CIN2+
among women harboring high-risk HPV. All statistical procedures
were carried out in R (R Software 2.9, www.r-project.org).
Results
From May 1996 through December 2007, a total of 731 HIV-
infected women enrolled into the cohort. The following women
were considered ineligible for the present study: virgins (2 women),
women who underwent a previous CIN treatment (3 women), and
women who had undergone total hysterectomy (26 women).
Eighty-nine women failed to attend their colposcopy appointment
Cervical Intraepithelial Neoplasia among HIV+
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and were thus excluded. Out of the 611 women who attended
their colposcopy appointment, 245 women had the exam
performed more than six months from their baseline assessment
and were thus excluded. Three hundred and sixty six women were
included in this analysis.
The median age of the women was 34 years (interquartile range
(IQR): 28–41 years), 55.1% were non-white, and 23.1% reported
a maximum of four years of formal education (Table 1). Forty-
three percent of the women were married or were living with a
partner and 59.6% reported current sexual partners. The median
age of first sexual intercourse was 17 years (IQR: 15–19 years), and
the median number of lifetime sexual partners was 4 (IQR: 3–9
lifetime partners). Forty-four percent of the women reported
tobacco use. The median number of pregnancies was 2 (IQR: 1–
4). The median nadir CD4 count was 273 cells/mm3 (IQR: 133–
439 cells/mm3) while the median baseline CD4 count was 347
cells/mm3 (IQR: 193–546 cells/mm3). Seventy-three percent of
the women were HAART-naive or had used HAART for fewer
than 60 days prior to cohort entry. The median time since the last
Pap test was 12 months (IQR: 8–30 months). A previous history of
an HPV infection was reported by 17.9% of the women. Vaginal
intraepithelial neoplasia (VaIN) and/or vulvar intraepithelial
(VIN) were diagnosed in 6.8% of the women.
The final composite colposcopy-histopathology diagnoses re-
vealed no abnormality in 74.0% (95%CI 70.0–80.0) of the women
(Table 2). The prevalence of CIN1, CIN2 and CIN3 were 20.0%
(95%CI 16.0–24.0), 3.5% (95%CI 1.6–5.5), and 2.2% (95%CI
0.7–3.7), respectively. One woman was found to have invasive
cervical cancer. The prevalence of CIN2+ among all women was
6.0% (95%CI 4.0–9.0). High-risk HPV was detected in all women
found to have CIN2/3, as well as in the patient with invasive
cervical cancer. The prevalence of CIN2+ among high-risk HPV
infected women was 12.8% (95%CI 7.7–18.0).
Factors associated with CIN2+ diagnosis in the bivariate
analysis were age, marital status/living with a partner, number
of lifetime sexual partners, tobacco use, number of pregnancies,
nadir CD4+ T-cell count, AIDS defining illness, HAART use, and
intraepithelial neoplasia of the lower genital tract (VIN and/or
VaIN) (p-value ,0.20 for all, Table 3). Factors that remained
independently associated with CIN2+ diagnosis in the multivariate
model (Table 3) were age,35 years when compared to$35 years
(aPR = 3.22 95%CI 1.23–8.39), current tobacco use (aPR = 3.69
Table 1. Socio-demographic, behavioral and clinical
characteristics of the HIV-infected women.
Characteristic (N) Neg/CIN1 (%) CIN2+ (%) Total (%)
Age (years) (N = 364)
,35 172 (50.3) 15 (68.2) 187 (51.3)
$35 170 (49.7) 7 (31.8) 177 (48.7)
Race/ethnicity (N = 363)
White 153 (44.9) 10 (45.5) 163 (44.9)
Non-white 188 (55.1) 12 (54.5) 200 (55.1)
Years of formal education (N = 363)
,5 81 (23.8) 3 (13.6) 84 (23.1)
5–8 117 (34.3) 8 (36.4) 125 (34.5)
.8 14 3(41.9) 11 (50.0) 154 (42.4)
Married/living with partner (N = 364)
Yes 152 (44.4) 6 (27.3) 158 (43.4)
No 190 (55.6) 16 (72.7) 206 (56.6)
Age at first sexual intercourse (years) (N = 300)
#16 140 (41.4) 12(54.5) 185 (51.4)
.16 198 (58.6) 10 (45.5) 175 (48.6)
Current sexual partners (N = 364)
Yes 202 (59.1) 15 (68.2) 217 (59.6)
No 140 (40.9) 7 (31.8) 147 (40.4)
Number of lifetime sexual partners (N = 361)
0–1 35 (10.3) 3 (13.6) 38 (10.5)
2–3 96 (28.3) 2 (9.1) 98 (27.2)
4 or more 208 (61.4) 17 (77.3) 225 (62.3)
Tobacco use (N = 363)
Yes, current tobacco use 65(19.1) 9 (40.9) 74 (20.4)
Yes, previous tobacco use 85 (24.9) 2 (9.1) 87 (24.0)
No 191 (56.0) 11 (50.0) 202 (55.6)
Number of pregnancies (N = 363)
None 28 (8.2) 3 (8.5) 31 (8.5)
One 80 (23.5) 2 (9.1) 82 (22.6)
$2 233 (68.3) 17(77.3) 250 (68.9)
Number of vaginal deliveries (N = 359)
None 143 (42.4) 7 (31.8) 150 (41.8)
One 84 (24.9) 8(36.4) 92 (25.6)
$ 2 110 (32.6) 7 (31.8) 117 (32.6)
Use of contraceptive hormones (oral/injectable) (N = 364)
Yes 26 (7.6) 1 (4.5) 27 (7.4)
No 316 (92.4) 21 (95.5) 337 (92.6)
Nadir CD4+ T-cell count (cells/mm3) (N = 342)
,350 196 (60.9) 17 (85.0) 213 (62.3)
$350 126 (39.1) 3 (15.0) 129 (37.7)
Baseline CD4+ T-cell count (cells/mm3) (N = 303)
,350 141 (49.8) 13 (65.0) 154 (50.8)
$350 142 (50.2) 7 (35.0) 149 (49.2)
AIDS defining illness (N = 366)
Yes 66 (19.2) 8 (36.4) 74 (20.2)
No 278 (80.8) 14 (63.6) 292 (79.8)
HAART for more than 60 days at cohort entry (N = 340)
Yes 80 (25.2) 10 (45.5) 90 (26.5)
No 238 (74.8) 12 (54.5) 250 (73.5)
Characteristic (N) Neg/CIN1 (%) CIN2+ (%) Total (%)
Time since last Pap test (N = 357)
#1 year 173 (51.6) 12 (54.5) 185 (51.8)
1–3 years 108 (32.2) 8 (36.2) 116 (32.5)
.3 years 54(16.1) 2 (9.1) 56 (15.7)
Self-reported history of HPV (N= 351)
Yes 57 (17.3) 6 (27.3) 63 (17.9)
No/does not know 272 (82.7) 16 (72.7) 288 (82.1)
VIN and/or VAIN (N = 322)
Yes 17 (5.6) 5 (23.8) 22 (6.8)
No 284 (94.4) 16 (76.2) 300 (93.2)
Percentages are given within the valid responses of each variable.
HAART: highly-active antiretroviral therapy, VIN: vulvar intraepithelial neoplasia,
VAIN: vaginal intraepithelial neoplasia.
doi:10.1371/journal.pone.0018297.t001
Table 1. Cont.
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95%CI 1.54–8.78), nadir CD4 T-cell count ,350 cells/mm3
when compared to $350 cells/mm3 (aPR = 6.03 95%CI 1.50 –
24.3) and concomitant diagnosis of VIN and/or VaIN (aPR =
2.68 95%CI 0.99–7.24).
In the stratified analysis that included only women harboring
high-risk HPV (Table 3), although many factors entered the initial
multivariate model, the procedure of removing factors with less
than 5% significance resulted in a final model with only one factor,
current tobacco use. Current tobacco use was associated with a
four-fold increase in the prevalence of CIN2+ (PR = 4.41 95%CI
1.90–10.27).
Discussion
Our study is the largest report from Latin America on CIN
prevalence in HIV-infected women confirmed by a composite
colposcopy-histopathology assessment. In this study, all cohort
participants received a standardized diagnostic colposcopic
examination. Invasive confirmatory diagnostic procedures (biopsy,
LLETZ, or cervical conization) were restricted to those with
colposcopic evidence of CIN, as per the Brazilian management
guidelines [15]. This approach avoided unnecessary invasive
diagnostic procedures while increasing the accuracy of CIN
diagnosis [21]. The women followed in our cohort benefit from
receiving gynecological and HIV care at the same institution
which maximizes completeness of clinical, laboratory and
antiretroviral use information. Also, it facilitates adherence to
study procedures thus allowing for inclusion of women from
different demographic and clinical profiles.
The prevalence of CIN is increased in women with HIV/AIDS
[22,23,24]. In our study, the observed prevalence of CIN2+ was
6.0%. A limited number of studies published in the literature used
colposcopy-histopathology confirmed diagnosis. A small case series
in Brazil reported a CIN2+ prevalence of 12.6% (N = 87) [25]
while a recent study conducted in India showed a prevalence of
CIN2+ of 16.5% (N = 303) [24] among HIV-infected women
using a composite colposcopy-histopathology diagnosis. Another
recent study from Rwanda found a 8.8% prevalence of CIN3+
(N = 476) among HIV/HPV co-infected women [22]; an equiv-
alent estimate from our analysis indicates a 4.9% (9/183)
prevalence of CIN3+ among HPV-infected women (Table 2).
Regional differences related to socio-economic factors, access to
antiretroviral therapy and gynecological care, as well as differences
in the profile of the women evaluated, may explain the different
findings. Moreover, the different findings might also be a result of
the different inclusion and exclusion criteria adopted in each study
(for example, the exclusion or inclusion of women previously
treated previously for CIN or women previously screened), and the
lack of consensus on the systematic biopsy of colposcopic findings.
Several factors previously identified as associated with cervical
cancer in the general female population were also shown to be of
importance in this cohort of HIV-infected women. We found that
the factors significantly and independently associated with CIN2+
diagnosis were younger age (,5 years), current tobacco use, lower
nadir CD4 count (,350 cells/mm3) and diagnosis of intraepithe-
lial neoplasia of the lower genital tract (VIN and/or VaIN, with
borderline significance).
Women become infected with HPV soon after sexual debut and
may develop CIN some years later. Accordingly, women between
the ages of 30 and 40 years are expected to suffer most from CIN.
Cervical cancer will generally affect women at a later age. For the
HIV-infected women included in this analysis, the median age of
first sexual intercourse was 17 years, and CIN2+ was most
significantly associated with the age of 35 years or younger. Our
finding is in accordance with other studies that have shown a
higher prevalence of CIN2+ among HIV-infected women in their
early/mid thirties [26,27]. The present study also demonstrated
that the prevalence of CIN2+ among the HIV-infected women
who use tobacco is almost four times greater than that found
among non-users. A significant association between a tobacco use
and cytological abnormalities was similarly reported for the HIV-
infected women of the WIHS cohort [27].
In the present study, the prevalence of CIN2+ among women
with a nadir CD4 T-cell count lower than 350 cells/mm3 was six
times greater than that observed for women with higher nadir. A
similar finding was observed in the recent study from Rwanda
[22]. In the Rwanda study, immunosuppression was significantly
associated with CIN3+ in women harboring non-HPV16 high-
risk HPV. In contrast, the recent study from India [24] did not
find an association of CIN2+ prevalence with immunosuppres-
sion, though in this study immunological status was measured at
study enrollment. In our study, the nadir CD4 T-cell count best
reflects the level of immunodeficiency reached by the women
since at cohort enrollment 27% of the women were already
receiving HAART for more than 2 months. Thus, it is probable
that some level of immune restoration in response to HAART
had already occurred in a fraction of the women. Our result
linking the level of immunodeficiency reached by the women in
her lifetime with CIN2+ prevalence is consistent with the role of
the immune response in controlling HPV infection and
consequently CIN progression. Also, it suggests that as the
CD4 T-cell count declines, vigilant follow up of the anogenital
tract is warranted.
In our study, intraepithelial neoplasia of the lower genital tract
was found to be significantly associated with CIN2+ in the
bivariate analysis. In the multivariate model, the prevalence of
CIN2+ among women diagnosed with VIN and/or VaIN was
almost three times greater when compared to those who did not
have such co-morbidities. Although this association only reached
borderline significance, we suspect that it might be of importance
given the relatively large effect size. Indeed, our sample size was
small which could have impacted our power to detect a significant
association of VIN and/or VaIN with CIN2+ prevalence. HIV-
infected women frequently have lower genital tract intraepithelial
neoplasia that is not limited to the cervix, and this has been well
documented in several studies conducted in large cohorts of HIV+
women in the United States [28,29,30]. This finding also
highlights the importance of having the vulvar, vaginal, and
Table 2. Prevalence of colposcopy-histopathology confirmed
cervical intraepithelial neoplasia (CIN) and invasive cervical
cancer (ICC) among HIV-infected women followed at the IPEC
cohort, stratified by human papillomavirus (HPV) infection.
All women HPV infection* High-risk HPV
N % 95% CI N % 95% CI N % 95% CI
Negative 271 74.0 [70.0–78.0] 111 60.6 [53.5–68.0] 100 58.1 [51.0–65.6]
CIN1 73 20.0 [16.0–24.0] 50 27.0 [21.0–34.0] 50 29.0 [22.2–36.0]
CIN2 13 3.5 [1.6–5.5] 13 7.0 [3.3–11.0] 13 7.6 [3.6–11.5]
CIN3 8 2.2 [0.7–3.7] 8 4.4 [1.4–7.4] 8 4.6 [1.5–7.8]
ICC 1 0.3 [0.0–0.8] 1 0.5 [0.0–1.6] 1 0.6 [0.0-1.7]
Total 366 100.0 - 183 100.0 - 172 100.0 -
*The HPV infection group includes women harboring either high-risk HPV and/
or low-risk HPV.
doi:10.1371/journal.pone.0018297.t002
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perianal regions of HIV-infected women evaluated during
gynecologic exams and colposcopy.
Our study has limitations. The cross sectional nature of the
study implies that we cannot infer causality because the
temporality of the associations is unknown, but we can raise
hypotheses and strengthen other evidence. The relatively small
sample size can also be regarded as a limitation being a product of
stringent exclusion and diagnostic criteria that, on the other hand,
validates the chosen sample with respect to the absence of disease
and its correct classification at baseline. Of note is the fact that the
prevalence of CIN2+ among women who presented for their
baseline colposcopic evaluation after 6 months of cohort entry is
the same as that found among women who presented within six
months, as requested in the study procedures [prevalence of
CIN2+ among women who presented within 6 months of cohort
entry 6.0% (95%CI 4.0–9.0) and among those who presented after
6 months of cohort entry 6.0% (95%CI 3.7–9.8)]. This finding
further strengthens the validity of our exclusion criteria for the
present analysis and suggests that the sample evaluated did not
suffer from selection bias. Finally, we do not have data on HIV
uninfected women for comparison.
In summary, our study shows a prevalence of CIN2+ of 6.0% in
the baseline visit of the women with HIV/AIDS included in the
IPEC/FIOCRUZ cohort. We found that the main factors
associated with CIN2+ diagnosis were younger age, current
tobacco use, more pronounced lifetime immunosuppression and
concomitant intraepithelial neoplasia of the lower genital tract.
The relative risk of invasive cervical cancer among women, as well
as those living with HIV infection, varies across countries or, as is
the case in Brazil, within regions of a country, on the basis of the
extent to which premature death due to other causes or early
detection of cancer prevents progression of precursor lesions to the
invasive stage [7]. Before the introduction of antiretroviral
Table 3. Unadjusted and adjusted prevalence ratios (PR) for
the association of factors with cervical intraepithelial
neoplasia (CIN)2+ for all HIV-infected women and for those
women harboring high-risk human papillomavirus (HR HPV)
infection.
All women HR HPV infected
Unadjusted Adjusted Unadjusted
Variable PR 95%Cl PR 95%Cl PR 95%Cl
Age (years)
,35 2.03 0.84–4.85a 3.22 1.23–8.39b 1.69 0.73–3.94a
$35 1.00 1.00 1.00
Race/ethnicity
White 1.00 1.00
Non-white 0.98 0.43–2.21 1.43 0.47–2.29
Years of formal education
,5 0.50 0.14–1.73 0.53 0.16–1.79
5–8 0.89 0.36–2.17 0.92 0.36–2.18
.8 1.00 1.00
Married/living with partner
Yes 1.00 1.00
No 2.04 0.82–5.09a 1.78 0.73–4.31a
Age at first sexual intercourse (years)
#16 years 1.64 0.72–3.71 1.77 0.80–3.90a
.16 years 1.00 1.00
Current sexual partners
Yes 1.45 0.60–3.47 1.27 0.54–3.0
No 1.00 1.00
Number of lifetime sexual partners
0–1 1.00 1.00
2–3 0.26 0.04–1.47a 0.26 0.05–1.14
$4 0.96 0.29–3.16 0.86 0.27–2.73
Current tobacco use
Yes 2.70 1.18–6.17b 3.69 1.54–8.78b 3.71 1.67–8.26b
No 1.00 1.00 1.00
Number of pregnancies
None 1.00 1.00
One 0.25 0.04–1.50a 0.36 0.07–1.96
$2 0.70 0.21–2.32 1.21 0.38–3.87
Number of vaginal deliveries
None 1.00 1.00
$1 1.53 0.62–3.77 1.95 0.84–4.52a
Use of contraceptive hormones (oral/injectable)
Yes 0.59 0.08–4.17 0.46 0.07–3.05
No 1.00 1.00
Nadir CD4+ T-cell count (cells/mm3)
,350 3.43 1.03–11.33b 6.03 1.50–24.3b 2.47 0.77–7.84a
$350 1.00 1.00 1.00
Baseline CD4+ T-cell count (cells/mm3)
,350 1.79 0.74–4.37 1.13 0.48–2.66
$350 1.00 1.00
AIDS defining illness
Yes 1.97 0.79–4.88a 1.66 0.73–3.75
All women HR HPV infected
Unadjusted Adjusted Unadjusted
Variable PR 95%Cl PR 95%Cl PR 95%Cl
No 1.00 1.00
HAART for more than 60 days at cohort entry
Yes 2.31 1.02–5.22b 1.87 0.85–4.12a
No 1.00 1.00
Time since last Pap test
#1 year 1.00 1.00
1–3 years 1.06 0.44–2.54 1.11 0.48–2.60
.3 years 0.55 0.12–2.36 0.55 0.13–2.24
Self-reported history of HPV
Yes 1.71 0.69–4.26 1.33 0.54–3.17
No/does not know 1.00 1.00
VIN and/or VAIN
Yes 4.26 1.60–11.29b 2.68 0.99–7.24 2.51 0.98–6.44a
No 1.00 1.00 1.00
ap-value ,0.20
bp-value ,0.05
HAART: highly-active antiretroviral therapy, VIN: vulvar intraepithelial neoplasia,
VAIN: vaginal intraepithelial neoplasia.
doi:10.1371/journal.pone.0018297.t003
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therapy, the lack of cervical cancer screening for HIV-infected
women probably had little influence on their life expectancies
because of high competing mortality associated with other causes,
such as tuberculosis and opportunistic infections. Currently, HIV-
infected women are living longer and may thus suffer from such
co-morbidity. In Brazil, universal access to HAART has been
provided by the Ministry of Health since 1996 and survival is on
the same order of magnitude as in high-resource countries [31].
Unfortunately, the incidence of cervical cancer among HIV-
infected women has not decreased in high-resource countries since
the introduction HAART [32,33]. It is likely that cervical cancer
will continue to be a significant problem especially among HIV-
infected women. High-quality cervical cancer screening, including
the high-coverage, has to be a public health priority. HIV/AIDS
care and treatment programs thus provide an ideal platform to
integrate cervical cancer prevention activities in countries that face
a dual burden of both AIDS and cervical cancer.
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